EP2062572A1 — Pharmaceutical compositions
Assigned to Teva Pharmaceutical Industries Ltd · Expires 2009-05-27 · 17y expired
What this patent protects
The present invention provides a process of preparing a formulation with a sufficiently high dissolution rate and good bioavailability, which reduces the effect of the active material's physical characteristics on the chemical and physical properties of the final product.
USPTO Abstract
The present invention provides a process of preparing a formulation with a sufficiently high dissolution rate and good bioavailability, which reduces the effect of the active material's physical characteristics on the chemical and physical properties of the final product.
Drugs covered by this patent
- Mobic (MELOXICAM) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.